What Is Happening With Scopus BioPharma Stock On Thursday? - Scopus BioPharma (OTC:SCPS)

Scopus BioPharma Inc SCPS has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune.
Related Content: Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition.
The Duet Platform is comprised of three technologies, including RNA silencing (DUET-01), Antisense (DUET-02), and Protein degradation (DUET-03).
DUET-01 is in Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma.
In 2022, Duet is targeting to file two INDs for DUET-02 in two separate indications: genitourinary and head & neck cancers.
Duet is also evaluating combination therapies with checkpoint inhibitors.
Price Action: SCPS stock is up 30.50% at $6.54 during the market session on the last check Thursday, before the trading was halted.